Skip to main content
. 2017 Oct 6;8(58):98524–98532. doi: 10.18632/oncotarget.21567

Table 1. Comparison of PD-L1 status between four assays using various cut-offs.

assays/cut-offs Numbers of positive cases (%)
≥1% ≥5% ≥10% ≥25% ≥50%
22C3 34/97 (35%) 28/97 (29%) 26/97 (27%) 15/97 (15%) 12/97 (12%)
SP263 33/97 (34%) 26/97 (27%) 19/97 (19%) 11/97 (11%) 4/97 (4%)
SP142 16/97 (16%) 6/97 (6%) 3/97 (3%) 1/97 (1%) 0
E1L3N 23/97 (24%) 17/97 (18%) 13/97 (13%) 8/97 (8%) 4/97 (4%)